NYSEAMERICAN:PLX - Protalix Biotherapeutics News Headlines

$0.23
0.00 (0.00 %)
(As of 09/15/2019 08:51 AM ET)
Today's Range
$0.2180
Now: $0.2275
$0.23
50-Day Range N/A
52-Week Range
$0.19
Now: $0.2275
$0.83
Volume55,581 shs
Average Volume419,111 shs
Market Capitalization$33.76 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Protalix Biotherapeutics (NYSEAMERICAN PLX) News Headlines

Source:
DateHeadline
Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE AmericanProtalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American
finance.yahoo.com - August 30 at 9:31 PM
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX): Is Breakeven Near?Protalix BioTherapeutics, Inc. (NYSEMKT:PLX): Is Breakeven Near?
finance.yahoo.com - August 26 at 7:44 PM
Protalix Bio to evaluate alternatives to maximize shareholder valueProtalix Bio to evaluate alternatives to maximize shareholder value
seekingalpha.com - August 22 at 9:29 AM
Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic PartnershipsProtalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships
finance.yahoo.com - August 22 at 9:29 AM
Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeuticsShlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
finance.yahoo.com - August 13 at 11:47 PM
Edited Transcript of PLX earnings conference call or presentation 8-Aug-19 12:30pm GMTEdited Transcript of PLX earnings conference call or presentation 8-Aug-19 12:30pm GMT
finance.yahoo.com - August 11 at 8:11 PM
Protalix Biotherapeutics, Inc. (PLX) CEO Dror Bashan on Q2 2019 Results - Earnings Call TranscriptProtalix Biotherapeutics, Inc. (PLX) CEO Dror Bashan on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 9:12 AM
Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate UpdateProtalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update
finance.yahoo.com - August 8 at 9:34 AM
Protalix (PLX) Reports Q2 Loss, Tops Revenue EstimatesProtalix (PLX) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 8 at 9:34 AM
Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseProtalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
finance.yahoo.com - August 2 at 12:45 AM
Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019
finance.yahoo.com - July 30 at 12:18 AM
New finance chief at Protalix BioNew finance chief at Protalix Bio
seekingalpha.com - July 29 at 11:22 AM
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial OfficerProtalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
www.marketwatch.com - July 29 at 11:22 AM
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial OfficerProtalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
finance.yahoo.com - July 29 at 11:22 AM
Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?
finance.yahoo.com - July 11 at 6:25 PM
Protalix (PLX) Completes Enrollment in Fabry Disease StudyProtalix (PLX) Completes Enrollment in Fabry Disease Study
finance.yahoo.com - June 18 at 4:22 PM
Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry DiseaseProtalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
finance.yahoo.com - June 17 at 8:35 AM
Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United StatesProtalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
finance.yahoo.com - June 6 at 8:22 AM
Why Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.'s (WSE:PLX) High P/E Ratio Isn't Necessarily A Bad ThingWhy Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.'s (WSE:PLX) High P/E Ratio Isn't Necessarily A Bad Thing
finance.yahoo.com - May 31 at 6:53 PM
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and DirectorProtalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
www.marketwatch.com - May 21 at 7:26 PM
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and DirectorProtalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
finance.yahoo.com - May 21 at 7:26 PM
Przetwórstwo Tworzyw Sztucznych Plast-Box S.A. (WSE:PLX) Delivered A Weaker ROE Than Its IndustryPrzetwórstwo Tworzyw Sztucznych Plast-Box S.A. (WSE:PLX) Delivered A Weaker ROE Than Its Industry
finance.yahoo.com - May 9 at 8:22 AM
Edited Transcript of PLX earnings conference call or presentation 6-May-19 12:30pm GMTEdited Transcript of PLX earnings conference call or presentation 6-May-19 12:30pm GMT
finance.yahoo.com - May 7 at 8:26 AM
Protalix Biotherapeutics, Inc. (PLX) CEO Moshe Manor on Q1 2019 Results - Earnings Call TranscriptProtalix Biotherapeutics, Inc. (PLX) CEO Moshe Manor on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:39 PM
Protalix (PLX) Reports Q1 Loss, Tops Revenue EstimatesProtalix (PLX) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 6 at 7:39 PM
Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate UpdateProtalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update
www.marketwatch.com - May 6 at 8:23 AM
Protalix (PLX) to Report Q1 Earnings: Whats in the Cards?Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
www.msn.com - May 2 at 7:59 PM
Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019
finance.yahoo.com - April 29 at 8:17 AM
Do Options Traders Know Something About Protalix (PLX) Stock We Dont?Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
finance.yahoo.com - March 19 at 7:45 PM
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
finance.yahoo.com - March 19 at 7:45 PM
Protalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q4 2018 Results - Earnings Call TranscriptProtalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 18 at 8:00 PM
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate UpdateProtalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
finance.yahoo.com - March 18 at 8:17 AM
Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference CallProtalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
finance.yahoo.com - March 13 at 7:07 PM
When Will Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Turn A Profit?When Will Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Turn A Profit?
finance.yahoo.com - March 12 at 10:48 PM
Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019
finance.yahoo.com - March 6 at 8:27 AM
Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019 - GlobeNewswireProtalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019 - GlobeNewswire
globenewswire.com - February 7 at 6:42 PM
The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOsThe Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
feeds.benzinga.com - February 3 at 1:08 PM
Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfaProtalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa
www.nasdaq.com - January 28 at 6:20 PM
Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019 - GlobeNewswireProtalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019 - GlobeNewswire
globenewswire.com - January 28 at 8:18 AM
Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
finance.yahoo.com - January 28 at 8:18 AM
Does The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Share Price Tend To Follow The Market?Does The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Share Price Tend To Follow The Market?
finance.yahoo.com - January 26 at 5:47 PM
Implied Volatility Surging for Protalix (PLX) Stock OptionsImplied Volatility Surging for Protalix (PLX) Stock Options
finance.yahoo.com - January 18 at 5:44 PM
Moving Average Crossover Alert: Protalix BioTherapeuticsMoving Average Crossover Alert: Protalix BioTherapeutics
finance.yahoo.com - December 18 at 8:22 AM
Protalix completes enrollment in late-stage study of PRX-102 in FabryProtalix completes enrollment in late-stage study of PRX-102 in Fabry
seekingalpha.com - December 17 at 5:43 PM
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry DiseaseProtalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
finance.yahoo.com - December 17 at 8:18 AM
Protalix BioTherapeutics down 4% on Q3 resultsProtalix BioTherapeutics down 4% on Q3 results
seekingalpha.com - November 7 at 5:47 PM
Protalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q3 2018 Results - Earnings Call TranscriptProtalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 5:47 PM
Protalix: 3Q Earnings SnapshotProtalix: 3Q Earnings Snapshot
finance.yahoo.com - November 7 at 5:47 PM
Protalix (PLX) Reports Q3 Loss, Lags Revenue EstimatesProtalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 7 at 5:47 PM
Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate UpdateProtalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
finance.yahoo.com - November 7 at 8:20 AM
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel